ANCHIANO THERAPEUTICS LTD. AND THE BANK OF NEW YORK MELLONDeposit Agreement • January 13th, 2023 • Chemomab Therapeutics Ltd. • Pharmaceutical preparations • New York
DEPOSIT AGREEMENT dated as of February 14, 2019 among ANCHIANO THERAPEUTICS LTD., a company incorporated under the laws of Israel (herein called the Company), THE BANK OF NEW YORK MELLON, a New York banking corporation (herein called the Depositary), and all Owners and Holders (each as hereinafter defined) from time to time of American Depositary Shares issued hereunder.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • January 13th, 2023 • Chemomab Therapeutics Ltd. • Pharmaceutical preparations • Louisiana
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered between Chemomab Therapeutics, Inc. (the “Company”), a Delaware corporation, and Dale Pfost (the “Executive”), as of September 1, 2021 (the “Effective Date”). The Company is a wholly-owned subsidiary of Chemomab Therapeutics Ltd., an Israeli company and the parent company of the Company (the “Parent”), whose American Depositary Shares (“ADSs”) are listed for trading on the Nasdaq Stock Market.
CONSULTING AGREEMENTConsulting Agreement • January 13th, 2023 • Chemomab Therapeutics Ltd. • Pharmaceutical preparations
THIS AGREEMENT (the “Agreement”) is made on this 18 of April, 2022 between ChemomAb Ltd., a private company number 514694991, whose address is at Kiryat Atidim, Building 7, Tel-Aviv, Israel (the “Company”) and Prof. Kobi George and Dr. Adi Mor LTD, a private company number 515520542, whose address is at 15 Kafrisin St., Tel-Aviv Israel (the “Consultant”) and Dr. Adi Mor, Identification number 043017318 whose address is at 15 Kafrisin St., Tel-Aviv Israel (“Consultant’s Representative”)
